These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7809890)

  • 21. Breast cancer and neoadjuvant therapy: any predictive marker?
    Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
    Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proposed reference value of the CA 125 tumour marker in men. Potential applications in clinical practice.
    Barceló B; Ayllón O; Belmonte M; Barceló A; Vidal R; Forteza-Rey J; Gutiérrez A
    Clin Biochem; 2008 Jun; 41(9):717-22. PubMed ID: 18371306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of disseminated tumour cells as a potential surrogate-marker for monitoring palliative chemotherapy in colorectal cancer patients.
    Staritz P; Kienle P; Koch M; Benner A; von Knebel Doeberitz M; Rudi J; Weitz J
    J Exp Clin Cancer Res; 2004 Dec; 23(4):633-9. PubMed ID: 15743034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bladder cancer-associated nuclear matrix proteins.
    Getzenberg RH; Konety BR; Oeler TA; Quigley MM; Hakam A; Becich MJ; Bahnson RR
    Cancer Res; 1996 Apr; 56(7):1690-4. PubMed ID: 8603421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cystosarcoma phylloides of the breast. A retrospective analysis of 12 cases].
    Mallebré B; Ebert A; Perez-Cantó A; Hopp H; Opril F; Weitzel H
    Geburtshilfe Frauenheilkd; 1996 Jan; 56(1):35-40. PubMed ID: 8852784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum tumor markers. Part I: Clinical utility.
    Hoefner DM
    MLO Med Lab Obs; 2005 Dec; 37(12):20, 22-4. PubMed ID: 16435773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Are the ATS (American Thoracic Society) and the ERS (European Respiratory Society) correct in not recommending routine tumor marker assays foeening, staging, or evaluation of non-small cell lung cancer?].
    Watine J; Charet JC
    Rev Mal Respir; 1999 Apr; 16(2):139-49. PubMed ID: 10339757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic value of bone and tumour markers in patients with malignant diseases.
    Oremek GM; Weis A; Sapoutzis N; Sauer-Eppel H
    Anticancer Res; 2003; 23(2A):987-90. PubMed ID: 12820336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?
    Bremnes RM; Sirera R; Camps C
    Lung Cancer; 2005 Jul; 49(1):1-12. PubMed ID: 15949585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
    Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Considerations in rational use of tumor markers in breast carcinoma].
    Crombach G
    Praxis (Bern 1994); 1998 Apr; 87(17):589-94. PubMed ID: 9623326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses.
    Voorzanger-Rousselot N; Garnero P
    Cancer Treat Rev; 2007 May; 33(3):230-83. PubMed ID: 17433551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for the clinical use of tumour markers.
    Duffy MJ
    Ann Clin Biochem; 2004 Sep; 41(Pt 5):370-7. PubMed ID: 15333188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease.
    Doweck I; Barak M; Uri N; Greenberg E
    Br J Cancer; 2000 Dec; 83(12):1696-701. PubMed ID: 11104568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of tumour markers in cancer diagnosis and treatment.
    Higgins C
    Nurs Times; 1996 Apr 17-23; 92(16):36-7. PubMed ID: 8710591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients.
    Marchetti A; Buttitta F; Bertacca G; Zavaglia K; Bevilacqua G; Angelucci D; Viacava P; Naccarato A; Bonadio A; Barassi F; Felicioni L; Salvatore S; Mucilli F
    J Pathol; 2001 Sep; 195(2):186-90. PubMed ID: 11592097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carcinoembryonic antigen and CA19-9: implications of quantitative marker measurement in tissues for prognosis of colorectal cancer.
    Gebauer G; Müller-Ruchholtz W
    Cancer Detect Prev; 2001; 25(4):344-51. PubMed ID: 11531011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.